On August 24, 2026, the FDA published a drug recall for Thyroid Tablets, USP 30 mg. Vitruvias Therapeutics Inc. is voluntarily recalling one lot to the consumer level after testing confirmed the potential for the product to be superpotent.
Reason for recall
The affected lot may contain more thyroid hormone than labeled. Consumption of superpotent thyroid tablets can cause hyperthyroidism, which may present as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate or heart rhythm disturbances.
Three patient populations face elevated risk, particularly over extended periods:
- Elderly patients. Excess thyroid hormone levels in older adults have been associated with adverse outcomes, particularly cardiac.
- Pregnant patients. Overtreatment of hypothyroidism during pregnancy is associated with higher rates of maternal and fetal complications, including premature delivery and low birth weight.
- Infants. Overtreatment of hypothyroidism in infants may negatively affect growth and development.
-
Pharmacy required action
Check inventory immediately. Identify whether the product is in inventory, stop using and dispensing it, and return it to the place of purchase or as directed in the recall notification.
Counsel patients not to stop therapy on their own. Patients should not discontinue the medication without contacting their healthcare provider. Any patient experiencing a problem while taking this product should contact their physician.
That second point carries more weight than it may appear to. A recall notice reaching a patient without context invites them to simply stop taking a thyroid medication, which creates a different clinical problem than the one the recall is meant to solve.
Recall details
Reporting adverse events
Report adverse events related to this or any other drug product to MedWatch, the FDA Safety Information and Adverse Event Reporting Program:
- Complete and submit the MedWatch Online Voluntary Reporting Form online
- Download FDA Form 3500, or call 1-800-332-1088 to request a reporting form, then complete and return it to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178
Reference
U.S. Food and Drug Administration. (2026). Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets USP, 30 mg Due to Potential Product Quality Issue. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
.jpg)
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.